LB208
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Triple-Negative Breast Cancer (TNBC), Hepatocellular Carcinoma (HCC), Ovarian Cancer
Key Facts
About Leukos Biotech
Leukos Biotech is a private, preclinical-stage biotech company founded in 2016 and based in Barcelona, Spain. The company's core innovation is targeting the serotonin receptor 1B (HTR1B) on cancer stem cells and refractory cells, using a proprietary chemical space to develop novel therapeutics and companion diagnostics. Its lead asset, LB208, is being co-developed with AOP Health for indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and several solid tumors, with an IND expected in 2023. The company is backed by venture capital and non-profit foundation investors.
View full company profile